WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Bortezomib
Related studies linked through entity extraction aliases.
Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
- Status
- COMPLETED
- Phase
- PHASE1
Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)
- Status
- COMPLETED
- Phase
- PHASE2
Safety and Efficacy of Desensitization Therapy in Sensitized Participants Awaiting Heart Transplantation
- Status
- TERMINATED
- Phase
- PHASE2
Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
- Status
- TERMINATED
- Phase
- PHASE1
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant
- Status
- COMPLETED
- Phase
- PHASE2
Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease
- Status
- COMPLETED
- Phase
- PHASE2
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE1
Bortezomib in Patients With Chronic Graft Versus Host Disease
- Status
- COMPLETED
- Phase
- PHASE1
S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation
- Status
- TERMINATED
- Phase
- PHASE2
Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance
- Status
- WITHDRAWN
- Phase
- PHASE2